Literature DB >> 6438245

Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination.

I Mohammed, G C Onyemelukwe, E N Obineche, N Gupta, G O Oyeyinka.   

Abstract

Meningococcal antibody was measured in 928 persons vaccinated with combined groups A and C polysaccharide antigens in Bauchi State, Nigeria between 1979 and 1982. Protective amounts of antibody were detected by the indirect haemagglutination technique up to 4 years after vaccination. This persistence was observed mainly in adults, although a substantial proportion of older children also had persistent antibody. Titres in younger children fell progressively, and by the third year the mean log2 antibody titre was 1.4; this may not confer protection against disease. A rational policy for vaccination against meningococcal meningitis would be to revaccinate younger children after 2 years, older children after 4 years, and adults after 6-8 or more years.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6438245     DOI: 10.1016/s0163-4453(84)91468-3

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  5 in total

Review 1.  Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.

Authors:  Idris Mohammed; Garba Iliyasu; Abdulrazaq Garba Habib
Journal:  Pathog Glob Health       Date:  2017-01-12       Impact factor: 2.894

2.  Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.

Authors:  Giannina Izquierdo; Juan Pablo Torres; M Elena Santolaya; M Teresa Valenzuela; Jeannette Vega; May Chomali
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.

Authors:  Mark A Miller; Cathryn K Shahab
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

5.  Two enzyme linked immunosorbent assays for detecting antibodies against meningococcal capsular polysaccharides A and C.

Authors:  O A Akinwolere; D S Kumararatne; R Bartlett; D M Goodall; D Catty
Journal:  J Clin Pathol       Date:  1994-05       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.